O
O. Chappey
Researcher at French Institute of Health and Medical Research
Publications - 23
Citations - 2666
O. Chappey is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Endothelium & Glycation. The author has an hindex of 14, co-authored 23 publications receiving 2551 citations.
Papers
More filters
Journal ArticleDOI
Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE.
Marie-Paule Wautier,O. Chappey,Stefano Corda,David M. Stern,Ann Marie Schmidt,Jean-Luc Wautier +5 more
TL;DR: Findings underscore a central role of NADPH oxidase in AGE-RAGE-mediated generation of ROS and provide a mechanism for altered gene expression in A GE-related disorders.
Journal ArticleDOI
Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.
Jean-Luc Wautier,C. Zoukourian,O. Chappey,M.-P. Wautier,P J Guillausseau,Rong Cao,Osamu Hori,David M. Stern,Ann Marie Schmidt +8 more
TL;DR: Data support the concept that ligation of AGEs by endothelial RAGE induces cellular dysfunction, at least in part by an oxidant-sensitive mechanism, contributing to vascular hyperpermeability in diabetes, and that RAGE is central to this pathologic process.
Journal ArticleDOI
Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications
Jean-Luc Wautier,M.-P. Wautier,Ann Marie Schmidt,G. M. Anderson,Osamu Hori,Clotilde Zoukourian,L Capron,O. Chappey,Shi Du Yan,J Brett +9 more
TL;DR: In this article, the authors hypothesized that formation of advanced glycation end products (AGEs) on the surface of diabetic erythrocytes could mediate their interaction with ECs leading to binding and induction of vascular dysfunction.
Journal ArticleDOI
Advanced glycation end products, oxidant stress and vascular lesions
TL;DR: An attempt to minimize AGE formation and to limit ROI production by an appropriate therapy may result in the reduction or slowing of vascular disease in patients with diabetes mellitus.
Journal ArticleDOI
Recombinant Advanced Glycation End Product Receptor Pharmacokinetics in Normal and Diabetic Rats
C. Renard,O. Chappey,M.-P. Wautier,M. Nagashima,E. Lundh,J. Morser,L. Zhao,A.-M. Schmidt,Jean Michel Scherrmann,J.-L. Wautier +9 more
TL;DR: This study showed that rR-RAGE was biologically active in vivo and slowly cleared, which suggests it could be considered as a potential therapy in patients with diabetes mellitus.